| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5687d729ee518b05ab6447c5419c217d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2002-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2cf16a3f6ae7b3d3ff6d41669e3ca44c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_234bdfefd3018e9ae1f65cc344334b6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_938c428e8ead487814564c10d56bf7be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08d7bf3fc8b4a7fe097055f043383b64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_093ac008a1c181af99752cfea1ebf557
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2075ea0ae5794a541957ec09f62108ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bba6739bbf4c1186601f4c77dd2b457 |
| publicationDate |
2004-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1403639-A1 |
| titleOfInvention |
Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases |
| abstract |
The invention relates to a method for determining whether a treatment of a disorder with an HDAC inhibitor is to be started/continued or not comprising determining the level of histone acetylation in the sample by use of an antibody capable of binding to acetylated histone, and classifying the disorder as to be treated with an HDAC inhibitor when the level of histone acetylation is significantly lower than that of a reference sample. The invention further relates to the diagnostic and prognostic use of specific antibodies and cell lines producing them. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005085864-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9389223-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010032093-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019122127-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006042035-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1896849-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006042035-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1896849-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2039355-A2 |
| priorityDate |
2002-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |